title: Targeting cancer cell metabolism in pancreatic adenocarcinoma.
abstract: Pancreatic ductal adenocarcinoma (PDAC) is expected to become the second leading cause of cancer death by 2030. Current therapeutic options are limited, warranting an urgent need to explore innovative treatment strategies. Due to specific microenvironment constraints including an extensive desmoplastic stroma reaction, PDAC faces major metabolic challenges, principally hypoxia and nutrient deprivation. Their connection with oncogenic alterations such as KRAS mutations has brought metabolic reprogramming to the forefront of PDAC therapeutic research. The Warburg effect, glutamine addiction, and autophagy stand as the most important adaptive metabolic mechanisms of cancer cells themselves, however metabolic reprogramming is also an important feature of the tumor microenvironment, having a major impact on epigenetic reprogramming and tumor cell interactions with its complex stroma. We present a comprehensive overview of the main metabolic adaptations contributing to PDAC development and progression. A review of current and future therapies targeting this range of metabolic pathways is provided.
authors.affiliation: INSERM U728, Beaujon University Hospital (AP-HP - PRES Paris 7 Diderot), Clichy La Garenne, France.
authors.forename: Romain
authors.initials: R
authors.lastname: Cohen
authors.affiliation: INSERM U728, Beaujon University Hospital (AP-HP - PRES Paris 7 Diderot), Clichy La Garenne, France.|Department of Medical Oncology, Henri Mondor University Hospital, Créteil, France.
authors.forename: Cindy
authors.initials: C
authors.lastname: Neuzillet
authors.affiliation: AAREC Filia Research, Translational Department, Boulogne-Billancourt, France.
authors.forename: Annemilaï
authors.initials: A
authors.lastname: Tijeras-Raballand
authors.affiliation: Medical Oncology, Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
authors.forename: Sandrine
authors.initials: S
authors.lastname: Faivre
authors.affiliation: New Drug Evaluation Laboratory, Centre of Experimental Therapeutics and Medical Oncology, Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
authors.forename: Armand
authors.initials: A
authors.lastname: de Gramont
authors.affiliation: Medical Oncology, Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
authors.forename: Eric
authors.initials: E
authors.lastname: Raymond
mesh_terms: D000818:Animals; D021441:Carcinoma, Pancreatic Ductal / Q000378:metabolism* / Q000473:pathology*; D018450:Disease Progression; D006801:Humans; D010190:Pancreatic Neoplasms / Q000378:metabolism* / Q000473:pathology*
keywords: glutamine; glycolysis; hypoxia; metformin; warburg effect